Nicolas Constantin

Mr. Nicolas Constantin

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2022 in Epigenomes
Verified
Journal Article
Open access
PDF file
NCNicolas Constantin
Nicolas Constantin
ASAbu Ali Ibn Sina
Abu Ali Ibn Sina
Darren KorbieDarren Korbie
Darren Korbie
MTMatt Trau
Matt Trau
The efficiency of conventional screening programs to identify early-stage malignancies can be limited by the low number of cancers recommended for screening as well as the high cumulative false-positive rate, and associated iatrogenic burden, resulting from repeated multimodal testing. The opportunity to use minimally invasive liquid biopsy testing to screen asymptomatic individuals at-risk for multiple cancers simultaneously could benefit from the aggregated diseases prevalence and a fixed specificity. Increasing both latter parameters is paramount to mediate high positive predictive value—a useful metric to evaluate a screening test accuracy and its potential harm-benefit. Thus, the use of a single test for multi-cancer early detection (stMCED) has emerged as an appealing strategy for increasing early cancer detection rate efficiency and benefit population health. A recent flurry of these stMCED technologies have been reported for clinical potential; however, their development is facing unique challenges to effectively improve clinical cost–benefit. One promising avenue is the analysis of circulating tumour DNA (ctDNA) for detecting DNA methylation biomarker fingerprints of malignancies—a hallmark of disease aetiology and progression holding the potential to be tissue- and cancer-type specific. Utilizing panels of epigenetic biomarkers could potentially help to detect earlier stages of malignancies as well as identify a tumour of origin from blood testing, useful information for follow-up clinical decision making and subsequent patient care improvement. Overall, this review collates the latest and most promising stMCED methodologies, summarizes their clinical performances, and discusses the specific requirements multi-cancer tests should meet to be successfully implemented into screening guidelines.

28 August 2026 in Science Advances
Verified
Journal Article
Open access
ZZZhen Zhang
Zhen Zhang
EAEmtiaz Ahmed
Emtiaz Ahmed
NCNicolas Constantin
Nicolas Constantin
JLJennifer Lu
Jennifer Lu
SPStephanie Portelli
Stephanie Portelli
MTMatt Trau
Matt Trau
Cancer progression is driven by epigenetic reprogramming, where promoter hypermethylation of tumour-suppressor genes and global hypomethylation reshape gene regulation and cellular phenotypes, promoting oncogenesis and disease advancement. We previously introduced the Methylscape, a cancer-specific DNA methylation landscape characterized by clustered promoter hypermethylation and gene body hypomethylation that enhances DNA’s physical affinity for gold surfaces. Here, we demonstrate that Methylscape can be leveraged to monitor cancer progression. In a TGF-β-induced breast cancer epithelial-mesenchymal transition (EMT) model, we observe increased Methylscape enrichment of mesenchymal-state DNA, indicating that this method can sensitively detect subtle epigenetic remodelling linked to tumour progression. Using a gold-based DNA desorption enrichment strategy coupled with methylation sequencing and qPCR, we show that hypermethylated regions are preferentially enriched on gold surface. Finally, we developed a low-cost, disposable screen-printed electrode platform for stage-specific breast cancer monitoring. Together, these findings establish Methylscape as a promising biophysical biomarker for non-invasive, real-time monitoring of cancer progression, advancing its potential for clinical translation.

5 June 2024
Verified
Thesis
Closed access
NCNicolas Constantin
Nicolas Constantin
The University of Queensland's institutional repository, UQ eSpace, aims to create global visibility and accessibility of UQ’s scholarly research.